

# **APPENDIX C**

**(SUBSTITUTE DRAWINGS)**

**(Serial No. 10/006,009)**




Figure 1

2/22




Figure 2




Figure 3

3/22




Figure 4




Figure 5

4/22




Figure 6




Figure 7

5/22




Figure 8




Figure 9

6/22




Figure 10

7/22





Figure 11.




8/22

Fig. 12




9/22

Fig.13



10/22

Fig. 14



# Lactate acidose patient (H0224)

M10620 (H 0224)




Fig. 15A

# Lactate acidose patient (H0224)

12/22






Fig. 15B

13/22

Fig. 16



14/22




Fig. 17




Fig. 18

15/22





Fig. 19



16/22

Fig. 20


## Significant decrease of mtDNA in PBMC



17/22

Fig. 21

Copies mtDNA/cell for three individual patients







Fig. 22




Fig. 23





Fig. 24

## Adverse effects of antiretroviral therapy

Percentage of patients changing ART because of adverse effects  
(results from the ATHENA-study in the Netherlands)



# DNA-NASBA amplification





Fig. 25

22/22



**Fig. 26**